In normal cells, DNA methylation is rare in promoter-associated CpG islands but important to X-inactivation, genomic imprinting and repression of repetitive elements. During tumorigenesis hundreds to thousands of genes gain methylation in promoter-associated CpG islands, affecting many pathways including tumor- suppressor pathways. The causes of this massive switch in DNA methylation remain mysterious. Interestingly, some genes are refractory to abnormal de-novo methylation in cancer while others are frequently targeted. Deciphering the differences between CpG islands sensitive or resistant to aberrant methylation will lead to a better understanding of the cellular factors that modulate cancer-specific DNA hypermethylation. Based on preliminary data, our central hypothesis to explain this difference is that an interplay between local sequence features (repeat elements, recognition sites for DNA binding proteins) and baseline chromatin states (histone modifications) related to developmental transcription programs modulates CpG island methylation in cancer. To test this hypothesis, we propose the following specific aims: (1) Identify baseline genetic and epigenetic features which segregate genes with propensity to become de-novo methylated in cancer from genes protected from de-novo methylation;and (2) use cellular models of DNA methylation induction to validate the individual and cooperative action of candidate genetic and epigenetic features.
In specific aim 1, we propose (a) to measure the propensity of promoter-associated CpG islands to DNA hypermethylation in myeloid leukemia and colorectal carcinomas) and (b) to identify the genomic (transcription factor binding sites, retrotransposons, short direct repeats) and epigenomic (histone modifications in normal cells) factors that distinguish methylation-prone versus methylation-resistant CpG islands. Significant features will be entered in a mathematical model to reveal individual and cooperative activity in modulating methylation in cancer, and the model will be validated in other samples and tumor types. The most significant features and known factors associated with differential predisposition to DNA methylation (the transcription factor Sp1, LINE/SINE retrotransposons and the insulator proteins CTCF, USF1/2 and VEZF1) will be tested in specific aim 2. For this testing we will use a series of cellular models developed in our laboratory where engineered transgenes can be inserted in specific genomic loci, and later on moved in and out of repressive contexts due to the presence of tetracycline-induced repressors. We expect that the successful development of our research will bring novel insights in how abnormal DNA methylation is targeted to specific genes while sparing others, and will also result in the identification of multiple targets for epigenetic-based therapies.

Public Health Relevance

Alteration of the pattern of DNA methylation is observed in a large fraction of human cancers, and therapies targeting this epigenetic mark have proved effective in the treatment of several human neoplasias. How cancer cells acquire an altered DNA methylation profile is not fully understood, and we have found evidence that specific genes have an inherent predisposition to become methylated. In this study, we will perform a comprehensive evaluation of the genomic features associated with predisposition and resistance to DNA methylation, and we expect to derive a model that explains aberrant hypermethylation events observed in cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Li, Jerry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Sato, Takahiro; Cesaroni, Matteo; Chung, Woonbok et al. (2016) Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Res :
Raynal, Noël J-M; Lee, Justin T; Wang, Youjun et al. (2016) Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. Cancer Res 76:1494-505
Jin, Chunlei; Qin, Taichun; Barton, Michelle Craig et al. (2015) Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells. Epigenetics 10:1006-13
Yamazaki, Jumpei; Jelinek, Jaroslav; Lu, Yue et al. (2015) TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res 75:2833-43
Qin, Taichun; Si, Jiali; Raynal, Noël J-M et al. (2015) Epigenetic synergy between decitabine and platinum derivatives. Clin Epigenetics 7:97
Malouf, Gabriel G; Tahara, Tomomitsu; Paradis, Valérie et al. (2015) Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics 10:872-81
Jin, Chunlei; Lu, Yue; Jelinek, Jaroslav et al. (2014) TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res 42:6956-71
Maegawa, Shinji; Gough, Sheryl M; Watanabe-Okochi, Naoko et al. (2014) Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res 24:580-91
Tahara, Tomomitsu; Yamamoto, Eiichiro; Madireddi, Priyanka et al. (2014) Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology 146:530-38.e5
Tahara, Tomomitsu; Yamamoto, Eiichiro; Suzuki, Hiromu et al. (2014) Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74:1311-8

Showing the most recent 10 out of 16 publications